Status:
UNKNOWN
12 Fractions Carbon Ion Radiotherapy for Localized Prostate Cancer
Lead Sponsor:
Shanghai Proton and Heavy Ion Center
Conditions:
Radiotherapy
Prostate Cancer
Eligibility:
MALE
45-85 years
Phase:
NA
Brief Summary
The arm of this study is to explore the optimal dose of 12 fractions of carbon ion radiotherapy for prostate cancer in our center.
Detailed Description
The radiation dose of 51.6GyE in 12 fractions is currently widely used in Japan, and clinical studies of 51.6GyE/12Fx have also been carried out for SBRT. There are some differences in equipment and c...
Eligibility Criteria
Inclusion
- Pathologically confirmed adenocarcinoma of prostate
- Stage cT1-3N0M0 localized prostate cancer
- No lymph nodes or distant metastasis
- Age ≥ 45 and \< 85 years of age
- Karnofsky Performance Score ≥70
- No previous pelvic radiation therapy (RT)
- No previous prostatectomy
- No previous invasive cancer (within 5 years before the prostate cancer diagnosis)
- Ability to understand character and individual consequences of the clinical trial
- Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial
Exclusion
- No pathologically confirmed adenocarcinoma of the prostate
- Pelvic lymph node metastasis (N1)
- Distant metastasis (M1)
- Previous pelvic radiotherapy
- Previous prostatectomy
Key Trial Info
Start Date :
December 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04724577
Start Date
December 1 2019
End Date
June 1 2023
Last Update
November 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Proton and Heavy Ion Center
Shanghai, China